Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06804837 | Implement and Test Visual Consent Template and Process | terminated | N/A | 266 | Washington University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06897735 | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile(EDDIS-a1) | terminated | Phase 1 | 4 | Petrov, AndreyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04303858 |
| A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors |
| terminated |
| Phase 1 |
| 189 |
| Hoffmann-La RocheINDUSTRY |
| 5 |
| Jun 2, 2026 |
| clinicaltrials |
| NCT00744185 | Propranolol in Capillary Hemangiomas(HEMANGIOMA) | terminated | Phase 2 / Phase 3 | 14 | University Hospital, BordeauxOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03331601 | Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients | terminated | Phase 2 | 7 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03897491 | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma | terminated | Phase 2 | 17 | photonamic GmbH & Co. KGINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04123535 | Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma(HIFU-UPS) | terminated | N/A | 5 | Matthew BucknorOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04250051 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis(MITRAS) | terminated | Phase 2 | 29 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05224661 | Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events(MEASURE) | terminated | — | 303 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | terminated | — | 40 | University of OklahomaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05571969 | Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors | terminated | Phase 1 | 14 | Allarity TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)(LUNAR-4) | terminated | Phase 2 | 31 | NovoCure GmbHINDUSTRY | 7 | Jun 1, 2026 | clinicaltrials |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | terminated | Phase 3 | 190 | National Cancer Institute (NCI)NIH | 2 | May 29, 2026 | clinicaltrials |
| NCT05413915 | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | terminated | Phase 3 | 8 | Sarit AssoulineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05515406 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | terminated | Phase 1 | 9 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03946332 | Physical Activity for Myeloma Autograft Longitudinal Study(PAMAL) | terminated | N/A | 60 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06465017 | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer | terminated | N/A | 149 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06878248 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 10 | Calibr, a division of Scripps ResearchOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07082257 | Precision Performance Status Compared With ECOG Performance Status | terminated | — | 41 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT03765983 | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | terminated | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05903807 | [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer | terminated | Phase 2 | 20 | Aalborg University HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | terminated | Phase 3 | 102 | ImmunityBio, Inc.INDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT01421927 | Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma(REVALLO) | terminated | Phase 1 | 13 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | terminated | Phase 3 | 174 | Abnoba GmbhINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT02316548 | Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer | terminated | Phase 2 | 14 | NRG OncologyOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma(GCISAVE) | terminated | Phase 2 | 65 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03646461 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | terminated | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04169074 | Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial) | terminated | Phase 2 | 7 | University of ArizonaOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05839600 | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | terminated | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT01885949 | Tivozanib + Enzalutamide in Adv Prostate Cancer | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02995603 | Patient Experience and Acceptance of Horizontal Rotation(Nano-X) | terminated | N/A | 43 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT05368428 | Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer | terminated | N/A | 17 | Emory UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05911243 | Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer | terminated | N/A | 3 | University of WashingtonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Corcept TherapeuticsINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | terminated | Phase 2 | 225 | Iovance Biotherapeutics, Inc.INDUSTRY | 7 | May 15, 2026 | clinicaltrials |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 15 | Thomas HopeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05051345 | Increasing Access to Smoking Cessation and Smoke Free Home Services for Low-Income Pregnant Women in Northeast Texas | terminated | N/A | 191 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 3, 2026source: clinicaltrials